Vir Biotechnology, Inc. SEC Filings

Vir Biotechnology (VIR): Form 4 insider transaction — SVF Endurance (Cayman) Limited, an affiliate of SoftBank Vision Fund, reported open‑market sales executed under a Rule 10b5-1 trading plan. On 10/15/2025, it sold 16,671 shares of common stock at a weighted average price of $6.0702. On 10/16/2025, it sold 12,844 shares at a weighted average price of $6.1014. Following these transactions, indirect beneficial ownership is reported as 15,340,494 shares. The filing notes the weighted‑average price ranges for each date and offers to provide full trade‑by‑trade detail upon request.

Vir Biotechnology (VIR): A reporting group affiliated with SoftBank—SVF Endurance (Cayman) Limited—reported open‑market sales of Vir common stock under a Rule 10b5‑1 trading plan entered into on September 3, 2025. On 10/09/2025, it sold 249,060 shares at a weighted average price of $6.1428. On 10/10/2025, it sold 2,300 shares at a weighted average price of $6.0752.

Following these transactions, the filing shows beneficial ownership of 15,372,309 shares after the first sale and 15,370,009 shares after the second, held indirectly, with SVF Endurance as record holder and SB Investment Advisers (UK) Limited managing SoftBank Vision Fund (AIV M1) L.P. The reporting person is listed as a Director and 10% Owner.

SVF Endurance (Cayman) Ltd and related SoftBank entities reported insider sales of Vir Biotechnology, Inc. (VIR) common stock under a Rule 10b5-1 plan. The filings show a sale of 72,133 shares on 10/07/2025 at a weighted average price of $5.6029 and a sale of 466,242 shares on 10/08/2025 at a weighted average price of $6.0479. After the reported transactions, the beneficial ownership attributable indirectly to the reporting group declined from 16,087,611 shares to 15,621,369 shares. The filings state the sales were effected pursuant to a 10b5-1 trading plan entered on September 3, 2025, and identify SVF Endurance as a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited acting as AIFM.

SVF Endurance (Cayman) Ltd and affiliated reporting persons disclosed insider sales of 524,297 shares of Vir Biotechnology, Inc. (VIR) across two dates in early October 2025. The sales occurred on 10/03/2025 and 10/06/2025 at weighted average prices of approximately $5.5553 and $5.6878, respectively, and were executed under a Rule 10b5-1 trading plan established on 09/03/2025. Following these disposals the reporting group beneficially owned 16,159,744 shares.

The filing clarifies that SVF Endurance (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited appointed as the alternative investment fund manager responsible for investment decisions.

Vir Biotechnology, Inc. submitted a Form 144 notifying a proposed sale of 1668404 shares of its Common Stock through BTIG, LLC on the NASDAQ with an approximate aggregate market value of $9526586.84. The filing shows the shares were originally acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that had been purchased between August 2017 and January 2019, with 21666666 shares noted as the amount acquired and 01/31/2019 listed as a payment date. The issuer's total shares outstanding are listed as 138916426, and the proposed approximate sale date is 10/03/2025. The filer represents there are no undisclosed material adverse facts and indicates no securities were sold by this person in the past three months.

Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $5.8362 per share, with individual sale prices ranging from $5.68 to $5.99. After the reported disposition, the filing shows the reporting person beneficially owned 1,232,391 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and includes an undertaking to provide detailed per-price sale breakdowns on request.

Form 144 notice for Vir Biotechnology, Inc. (VIR) shows a proposed sale of 66,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $376,860.00, targeting an approximate sale date of 10/01/2025 on NASDAQ. The shares were originally acquired as pre-IPO stock from the issuer on 01/17/2017. The filer has completed prior Rule 10b5-1 plan sales of 22,000 shares on 09/02/2025 for $109,810.80 and 22,000 shares on 08/01/2025 for $109,698.60. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references a trading plan date field if relying on Rule 10b5-1.

Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares on 09/02/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $4.9914, with individual sale prices ranging from $4.88 to $5.07. After the reported sales, the filing shows 1,254,391 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and discloses that full breakdowns of shares sold at each price are available upon request.